UCB SA (OTCMKTS:UCBJY – Get Free Report) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $92.91 and traded as low as $77.62. UCB shares last traded at $79.88, with a volume of 104,130 shares changing hands.
UCB Trading Down 3.5 %
The company has a debt-to-equity ratio of 0.33, a current ratio of 1.19 and a quick ratio of 0.78. The company’s 50-day moving average is $92.17 and its two-hundred day moving average is $94.67.
About UCB
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.
Further Reading
- Five stocks we like better than UCB
- Investing In Automotive Stocks
- Viking Therapeutics Stock Pops But Struggles to Hold Gains
- Technology Stocks Explained: Here’s What to Know About Tech
- Qualcomm Stock Just Earned a Fresh Buy Rating—Get Excited
- What is a Death Cross in Stocks?
- Meta Stock Holds Upside Potential as Analysts Cut Price Targets
Receive News & Ratings for UCB Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UCB and related companies with MarketBeat.com's FREE daily email newsletter.
